TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02854579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: neural progenitor cell
Description: Neural progenitor cells are derived from the same aborted human fetal forebrain.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Paracrine factors
Description: The factors obtained from cultured human mesenchymal stem cells were concentrated 50 times

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: progenitor cell and paracrine factors
Description: Neural progenitor cells will be received after paracrine factors therapy
Study: NCT01379664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Isoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
Study: NCT01062256

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet administered orally as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guaifenesin
Description: One 400 mg immediate release tablet administered orally as a single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buckwheat Honey
Description: 10 mL administered orally as a single dose
Study: NCT03948347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: The treatment arm will receive the starting dose of liraglutide of 0.6 mg/d subcutaneously once daily, and the dose will be increased to 1.8 mg/d in two weeks, and then continue to administrate this dose for 90 days.
Study: NCT02315690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DHAp)
Description: In the fMDA arm, all individuals in the target area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: reactive case detection
Description: Individuals in RACD target areas will be tested by RDT and if positive will be taken to the nearest health facility for treatment as per program operating procedures.
Study: NCT01451762

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: .9 normal saline
Description: .9 normal saline administered before surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25 mg diphenhydramine IV
Description: 25 mg diphenhydramine IV administered before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg diphenhydramine IV
Description: 50 mg diphenhydramine administered IV before surgery
Study: NCT02506582

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: jerusalem artichoke and fermented soybeans powder mixture
Description: 40 g jerusalem artichoke and fermented soybean powder mixture

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 40 g powdered rice flour
Study: NCT01909557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl-L-carnitine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02430870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648
Description: TAK-648 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648
Description: TAK-648 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648
Description: TAK-648 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648
Description: TAK-648 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648
Description: TAK-648 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-648
Description: TAK-648 solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-648 placebo-matching solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-648 placebo-matching solution
Study: NCT03299296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 Milligrams
Description: The first group is to be on Rivaroxaban 10 mg with dosage according to the orthopedic approved regimen (10 mg once daily 6-10 hours after the surgery; recommended total duration of therapy: 12 to 14 days; The American College of Chest Physicians (ACCP) recommendation: Minimum of 10 to 14 days; extended duration of up to 35 days suggested.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe
Description: The other group will be administered the standard of care (SOC) enoxaparin as follows:~Once-daily dosing: 40 mg once daily, with initial dose within 9 to 15 hours before surgery, and daily for at least 10 days (or up to 35 days postoperatively) or until risk of deep venous thrombosis (DVT) has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation ≥12 hours preoperatively or ≥12 hours postoperatively; extended duration of up to 35 days suggested.
Study: NCT02242201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PNB Bupivacaine
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAI Ropivacaine
Description: Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAI liposomal bupivacaine
Description: Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Injection, weight-based dosage of 100 mcg - 300 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Injection, weight-based dosage of 100 mcg - 300 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Injection, weight-based dosage of 100 mcg - 300 mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Injection, 30 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Injection, 30 mg
Study: NCT01934673

Intervention type: OTHER
Intervention: No treatment given
Description: Patients will fill out a questionnaire by interview.
Study: NCT01895296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: somatostatin analogue pasireotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo s.c.
Study: NCT05084001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silver diamine fluoride
Description: topical application of the agent on tooth surface

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium fluoride varnish
Description: topical application of the agent on tooth surface

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: tonic water
Description: topical application of tonic water on tooth surface
Study: NCT02285738

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81mg/day for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81mg/day for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81mg/day for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81mg/day for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81mg/day for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81mg/day for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Daily dose of Simvastatin for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Daily dose of Simvastatin for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Daily dose of Simvastatin for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Daily dose of Simvastatin for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Daily dose of Simvastatin for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Daily dose of Simvastatin for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: participants will be observed for thrombotic evens for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: participants will be observed for thrombotic evens for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: participants will be observed for thrombotic evens for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: participants will be observed for thrombotic evens for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: participants will be observed for thrombotic evens for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: participants will be observed for thrombotic evens for 4 weeks
Study: NCT04625114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat
Description: Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D1-\>D5);

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D1-\>D5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat
Description: Standard of care (SOC) + Camostat mesilate (Foipan) 100mg 3 tablets 3 times a day for 5 consecutive days (D6-\>D10);

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SOC + placebo 500 mg 3 tablets 3 times a day for five consecutive days (D6-\>D10).
Study: NCT04494867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Core Warming
Description: Esophageal heat transfer device will be set to 42°C temperature after initial placement, and maintained at 42°C for the duration of treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard temperature management and treatment
Study: NCT02143765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiglinide
Description: three times a day, orally, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: three times a day, orally, for 12 weeks
Study: NCT03328780

Intervention type: DEVICE
Intervention: Hemocue and Rad-67 measurement
Description: Measurement of the hemoglobin level
Study: NCT02589171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neo Close Abdominal Closure
Description: Neo Close Abdominal Closure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carter Thomason Device
Description: Carter Thomason Device
Study: NCT04439396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: nonsteroidal anti-inflammatory drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: nonsteroidal anti-inflammatory drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: saline fluid injection
Study: NCT04345965

Intervention type: PROCEDURE
Intervention: Endovascular procedure
Description: Endovascular therapies for erectile dysfunction
Study: NCT01621165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Addition of prazosin to usual care (add-on study)
Description: Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
Study: NCT02164279

Intervention type: OTHER
Intervention: Urinary sample collection
Description: urinary sample collection will be done at the inclusion visit for the assessment of the microalbuminuria ( \< or \> than 100mg/L)

Intervention type: OTHER
Intervention: Urinary sample collection
Description: urinary sample collection will be done at the inclusion visit for the assessment of the microalbuminuria ( \< or \> than 100mg/L)
Study: NCT00998023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mynx Vascular Closure Device
Description: Comparison of two different vascular closure devices.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AngioSeal Vascular Closure Device
Description: Comparison of two different vascular closure devices.
Study: NCT00213421

Intervention type: DRUG
Intervention: Dermoval
Description: group 1 elevated corticosteroids : attack treatment 2 tubes of 10g (4t/d) decreasing treatment : one month: 2 tubes/J (2t/d); 2 months : 2 tubes 1d sur 2 (1d/j); 4 months : 2 tubes 2 fois /week (0,6t/d); 4 months : 2 tubes 1 fois /week (0,3t/d)fois /week (0,3t/d) group 2 low corticosteroids : for paucibullous form with weight \< 45kg attack treatment 1 tubes of 10g (1t/d)decreasing treatment 1 month : 1 tube every 2d (0,5t/d; 1 month : 1 tubes 2 fois /week (0,3t/d) 1 month : 1 tubes 1 fois/week (0,15t/d); for paucibullous form with weight \> 45kg or for multibullous form with weight \< 45kg attack treatment 2 tubes of 10g (2t/d)decreasing treatment 1 month : 2 tubes every 2j (1t/d; 1 month : 2 tubes 2 fois /week (0,6t/d) 1 month : 2 tubes 1 fois /week (0,3t/d)and for multibullous form attack with weigth \> 45kg treatment 3 tubes of 10g (3t/d)decreasing treatment 1 month : 3 tubes every 2days (1,5t/d) 1 month : 3 tubes 2 fois /week (1t/j)1 mois : 3 tubes 1 fois /week (0,45t/d)

Intervention type: DRUG
Intervention: Dermoval
Description: group 1 elevated corticosteroids : attack treatment 2 tubes of 10g (4t/d) decreasing treatment : one month: 2 tubes/J (2t/d); 2 months : 2 tubes 1d sur 2 (1d/j); 4 months : 2 tubes 2 fois /week (0,6t/d); 4 months : 2 tubes 1 fois /week (0,3t/d)fois /week (0,3t/d) group 2 low corticosteroids : for paucibullous form with weight \< 45kg attack treatment 1 tubes of 10g (1t/d)decreasing treatment 1 month : 1 tube every 2d (0,5t/d; 1 month : 1 tubes 2 fois /week (0,3t/d) 1 month : 1 tubes 1 fois/week (0,15t/d); for paucibullous form with weight \> 45kg or for multibullous form with weight \< 45kg attack treatment 2 tubes of 10g (2t/d)decreasing treatment 1 month : 2 tubes every 2j (1t/d; 1 month : 2 tubes 2 fois /week (0,6t/d) 1 month : 2 tubes 1 fois /week (0,3t/d)and for multibullous form attack with weigth \> 45kg treatment 3 tubes of 10g (3t/d)decreasing treatment 1 month : 3 tubes every 2days (1,5t/d) 1 month : 3 tubes 2 fois /week (1t/j)1 mois : 3 tubes 1 fois /week (0,45t/d)
Study: NCT01357278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation and patient education
Description: Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.~Patient education will be offered every eight week.
Study: NCT02066922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Delefilcon A contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narafilcon A contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Narafilcon A contact lens
Description: Commercially available silicone hydrogel contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Incremental prescription worn over contact lenses if needed to provide acceptable vision

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Incremental prescription worn over contact lenses if needed to provide acceptable vision
Study: NCT03619005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaginal Insert
Description: Daily administration of a placebo vaginal insert.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasterone 6.5 mg (0.50%) Vaginal Insert
Description: Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
Study: NCT01366508

Intervention type: OTHER
Group type: OTHER
Intervention: High calorie lunch
Description: Subject fed a standard high calorie lunch at 1pm

Intervention type: OTHER
Group type: OTHER
Intervention: High calorie lunch
Description: Subject fed a standard high calorie lunch at 1pm

Intervention type: OTHER
Group type: OTHER
Intervention: Breakfast
Description: At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at \~11:00 and at \~13:00. During this period the subject will be required to remain in the unit.

Intervention type: OTHER
Group type: OTHER
Intervention: Breakfast
Description: At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at \~11:00 and at \~13:00. During this period the subject will be required to remain in the unit.
Study: NCT03280797

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: 2ml blood taken into TruCulture tube

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Description: 2ml blood taken into TruCulture tube
Study: NCT04370665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate BBBD with Cerezyme
Description: Blood Brain Barrier Disruption via Exablate to deliver Cerezyme.~Other Names:~Exablate Neuro
Study: NCT03480425

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measuring extubation force
Description: Intubation of the esophagus of anesthetized participants who are having planned endotracheal intubate for surgery; inflation of the cuff; attachment of a force transducer to the tube connector; and gently tugging the tube out of the mouth. Then intubating the esophagus and repeating the tugging procedure. Meanwhile, the force of resistance to tugging is measured with a force transducer.
Study: NCT05647031

Intervention type: OTHER
Intervention: Qualitative study. Pain in competitive athletes with physical disabilities and techniques for its management.
Description: This study used a qualitative, exploratory and descriptive methodology, with a semi-structured interview technique. The purpose was to respond to the specific objectives set out in this research from the perspective of competitive athletes and sports agents (physiotherapist, coach and psychologist). The thematic cores that served as a script for the interview were for the athletes and sports agents 1) sporting characteristics of the professionals; 2) perception of how pain affects this type of athlete and what repercussions it has on the development of their sporting career, and 3) knowledge of techniques and/or strategies for pain management (athlete, coach and psychologist).~The interviews were conducted via skype. After transcription of all the interviews, validation by the interviewees was applied for the reliability of the research. Two types of triangulation were applied to ensure the quality of the data.
Study: NCT03759678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IB1001
Description: IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
Study: NCT03405402

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis
Study: NCT00938171

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia
Description: All patients will be then given adequate sedation with propofol and local anesthetic given by dermal infiltration in incision site and regional breast and axillary areas. The local anesthetic of choice will be 2 % lidocaine (Xylocaine) and 0.5% Bupivacaine (Marcaine) mixed with 7 % sodium bicarbonate and epinephrine (Bosmine)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: The method of general anesthesia for the GA group will be induced with fentanyl (1-2 μg/kg) and propofol (2.5 mg/kg). After placement of a laryngeal mask or endotracheal tube airway, anesthesia will be maintained with sevoflurane (end-tidal concentrations 1%-3%) in a 50% oxygen/nitrous oxide mixture.
Study: NCT02157220

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed bearing prosthesis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile bearing prosthesis
Study: NCT00814463

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MMSE
Description: Neurocognitive function via MMSE done every 3 months for length of study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: QOL via FACT-Br
Description: Quality of Life via FACT-BR every 3 months for length of study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI done every 3 months for the length of the study.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Post-operative SRS
Description: Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
Study: NCT00731705

Intervention type: PROCEDURE
Intervention: collection of peripheral blood and apheresis samples
Description: Sixty mL of peripheral blood will be collected from consenting eligible donors. Additionally, after the laboratory techniques have been fully evaluated, leukopheresis samples will also be collected.